Recro Pharma (REPH) Misses Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Recro Pharma (REPH) Misses Q1 EPS by 1c

Recro Pharma Reports First Quarter 2015 Financial Results

May 12, 2015 6:03 PM EDT

Strengthened Company with Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes

Encouraging Dex-IN Interim Analysis Results Support Continuation and Completion of On-Going Phase II Trial

MALVERN, Pa., May 12, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH), a specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain, today reported financial results for the first quarter ended March 31, 2015.

"With the acquisition of key assets from Alkermes, including the Phase III-ready IV/IM meloxicam,... More